Sentences with phrase «lung cancer trials»

In two advanced lung cancer trials, which we covered, new drugs targeting familiar faulty molecules showed promise.

Many lung cancer trials have traditionally excluded patients with brain metastases at baseline, expecting that the presence of metastases would create negative results that could in turn create the appearance of drug failure.

While most of the work was done in the lab, Ahuja says her colleagues have already started to put the panel into use in a lung cancer trial.

Not exact matches

Now a new clinical trial is under way, by New York's Mount Sinai, to test a vaccine to combat recurrence in some of the most deadly forms of cancer, including lung, breast, gynecological and bladder cancers.

Researchers from the Sichuan University in Chengdu inserted the re-engineered cells into a lung cancer patient participating in a clinical trial at the West China Hospital on October 28th, according to Nature.

said they will discontinue a late - stage trial of their experimental lung cancer drug after an interim analysis showed it would not meet the main goal of improving overall survival.

The trial results «should start to put Merck on a better commercial trajectory in lung cancer,» the analyst said in a Thursday note to investors.

The PD - 1 checkpoint inhibitor Keytruda hit its goals in a new trial in previously untreated non-small cell lung cancer patients, beating chemo at staving off cancer progression and extending patients» lives.

The timing of the news report alarmed investors, coming as the company waits for all - important data from a lung cancer drug trial which is seen as a game - changer for Astra.

HERERA: Merck (NYSE: MRK) was one of the best performing stocks on the blue chip Dow index today, after the drug company «s new type of lung cancer drug performed better than expected in a highly anticipated clinical trial.

In a mid-stage trial, 16 of 37 lung cancer patients given a placebo ahead of standard chemo wound up hospitalized with severely low white blood cell counts.

Along the same lines, Daniel Sessler, an anesthesiologist at Cleveland Clinic in Ohio, is leading two randomized trials looking at whether nerve blocks added to general anesthesia reduce metastases in patients undergoing surgery to remove either breast or lung cancer.

A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (SCLung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (SClung cancer (cancer (SCLC).

Other trials of this drug target in lung cancer have not worked, and the drugs» effects in colorectal cancer are also questionable, Stambolic says.

«This is a fairly niche effort in lung cancer care, and we'd like to see a national level clinical trial at some point,» he said.

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.

In a head - to - head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous - non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

«In the 20 years that I've been in practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and Drug Administration approval in March to treat such patients whose lung cancer progressed, despite standard chemotherapy.

For the new trial, hospitals enrolled patients with advanced, squamous non-small cell lung cancer whose disease had progressed despite initial chemotherapy.

But Deng says that the lung - cancer tumours targeted by their trial are not easily accessible.

The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed.

Unfortunately, the treatment had little effect on the survival of the terminally ill lung cancer patients in the first trial.

Findings were presented at the WCLC are based on the updated results of 12 lung cancer patients enrolled in the clinical trial with pembro and irinotecan or gemcitabine with or without vinorelbine or docetaxel.

«Clinical trial using immunotherapy drug combinations to treat lung cancer appears safe.»

Since the Lung Cancer Mutation Consortium trial began in 2009, many patients are now tested for mutated or altered genes before treatment.

The clinical trial being planned will test the treatment in both lung cancer patients and those with glioblastomas.

The trial also recorded fewer cases of lung cancer in those on the treatment, consistent with basic research findings hinting that the same inflammatory pathway may initiate or spur tumor growth.

To identify the relevant mutations the scientists analyzed the blood samples of 1,858 men from three independent cohorts in Europe and North America: the Swiss arm of the European Randomized Study for Prostate Cancer Screening, the large American Screening trial, Prostate, Lung, Colorectal, and Ovarian (PLCO), Princess Margaret Cancer Centre (University Health Network) and Mount Sinai Hospital (Sinai Health System) in Toronto.

Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90 % disease control and 59 % response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1

The actual disparity in number of cases between the two groups was small, with 129 lung cancers in all, and the trial wasn't set up to study that disease.

Called the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) and funded by the drug giant Novartis, the trial also found fewer cases of lung cancer in those on the treatment, rekindling basic research findings hinting that the same inflammatory pathway may initiate or spur the growth of such tumors.

The company also tested the virus in a 23 - person, early - stage trial against colorectal, lung, ovarian and skin cancers.

Researchers only discovered this process in the late 1990s, but they've already begun dozens of clinical trials to gauge whether infusing patients with these small RNAs works against a range of diseases, from lung infections to liver cancer to age - related macular degeneration, a sight - stealing condition that mainly affects people over the age of 50.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

Progression - free survival in the trial escalated from 3.5 months to 9.7 months with the addition of radiation therapy delivered to all the metastatic sites of lung cancer as well as the primary disease site.

These results are among the best in the field, offering a lot of hope to people with ALK - positive lung cancer,» says D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado Cancer Center and the trial's principal investicancer,» says D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado Cancer Center and the trial's principal investiCancer Center and the trial's principal investigator.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

One successful compound, named Exel 647, that targets nonsmall - cell lung cancer in previously untreated patients is now in a phase 2 clinical trial.

«More evidence for impact of lung cancer targeted therapy from practice - changing trial.»

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerllung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzecancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, SwitzerlLung Cancer Conference (ELCC) 2016 in Geneva, SwitzeCancer Conference (ELCC) 2016 in Geneva, Switzerland.

P: We found discodermolide [a drug from Discodermia, a sponge found in the Caribbean, the Bahamas, and the Gulf of Mexico], and it's gone through phase I clinical trials for treatment of solid tumors such as ovarian, pancreatic, breast, colon, or lung cancers.

«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»

Partnering with the U.S. Food and Drug Administration allowed Doebele and colleagues to access clinical trial data describing initial tumor response, PFS and OS for 305 patients with stage IIIb or IV non-small cell lung cancer on trials of ALK inhibitors and 355 similar patients on trials of immunotherapies directed at PD - 1.

Wolin and colleagues analyzed data from a large, ongoing clinical trial called the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (Ptrial called the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PTrial (PLCO).

The results of these animal trials may eventually help patients with colon, rectum, stomach, breast, or lung cancer.

Though the optimal scenario is actually estimated to catch fewer lung cancers than the criteria used in the National Lung Screening Trial (NLST) in the US, the authors predict this more stringent scenario would require fewer CT scans, and lead to fewer false positive screens and lung cancer overdiagnosis, which can lead to patient hlung cancers than the criteria used in the National Lung Screening Trial (NLST) in the US, the authors predict this more stringent scenario would require fewer CT scans, and lead to fewer false positive screens and lung cancer overdiagnosis, which can lead to patient hLung Screening Trial (NLST) in the US, the authors predict this more stringent scenario would require fewer CT scans, and lead to fewer false positive screens and lung cancer overdiagnosis, which can lead to patient hlung cancer overdiagnosis, which can lead to patient harm.

However, «there are still large gaps in the published literature to be addressed and these could be filled with large definitive prospective trials that evaluate the benefit of exercise in lung cancer patients.»

A new drug that targets not only common cancer - causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I / II clinical trial.

The researchers are currently enrolling patients with stage 4 lung cancer and will soon begin enrolling people with glioblastoma multiforme (brain cancer) in these phase II trials.